Correction to: Nature Medicine https://doi.org/10.1038/s41591-022-01919-8, published online 8 August 2022.
In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Feigin, A., Evans, E.E., Fisher, T.L. et al. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med 30, 606 (2024). https://doi.org/10.1038/s41591-022-02070-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02070-0
